Delays in Clinical Trials Present Pharma Companies With Opportunities to Evolve

COVID-19 has upended clinical trial timelines – putting billions of forecasted sales at risk and delaying getting life-saving treatments to patients. This analysis from Garima Kaul, Senior Director, Research and Insights, Decision Resources Group, part of Clarivate, and Jamie Munro, Executive Director, CIRS explores the opportunities that delays in clinical trials present for pharma companies. Which areas have been hit the hardest, and how are pharma companies and regulatory agencies adapting to new ways of working? Read more here.